Ropivacaine HCL raw material Ropivacaine HCL Powder

CAS:98717-15-8

MF: C17H27ClN2O

MW:310.86

EINECS:1312995-182-4

Specification​: 99% min Ropivacaine HCL Powder

Sample:Ropivacaine HCL Powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance: White

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Ropivacaine HCL Powder Usage and Synthesis.

Ropivacaine hydrochloride is a long-acting local anaesthetic of the amide group. Its fat solubility is greater than that of lidocaine and less than that of bupivacaine, and its anaesthetic strength is eight times that of procaine.

Because its products of metabolism in the liver also have local anaesthetic effect, so the effect is more lasting.

Mainly used for regional block anaesthesia and epidural anaesthesia, for postoperative and childbirth analgesia.

Ropivacaine is a single enantiomeric (S-shaped) long-acting amide local anaesthetic, with the same mechanism of action as other local anaesthetics, blocking nerve excitation and conduction by inhibiting sodium channels in nerve cells. The blocking effect on motor nerves is related to the concentration of the drug, the concentration of 0.2 per cent is better for sensory nerve blocking, but almost no motor nerve blocking effect; 0.75 per cent produces better motor nerve blocking effect.

Ropivacaine is one such new long-acting amide local anaesthetic with a long duration of action and anaesthetic and analgesic effects.

Uses and functions of Ropivacaine HCL.

This product is used for:

1, Surgical anaesthesia:

(1) Epidural anaesthesia, including caesarean section;

(2) Subarachnoid anaesthesia;

(3) Regional block.

2、Acute pain control:

(1) Continuous epidural infusion or intermittent single dose, e.g., postoperative or vaginal labour analgesia;

(2) Regional block.

Pharmacological Effects of Ropivacaine HCL.

Ropivacaine, the first pure levameric long-acting amide local anaesthetic, has both anaesthetic and analgesic effects, producing surgical anaesthesia in high doses and sensory blockade (analgesia) with limited non-progressive motor nerve block in low doses.

The addition of epinephrine did not alter the strength or duration of the blockade with ropivacaine. Ropivacaine reversibly blocks impulse conduction along nerve fibres by blocking the influx of sodium ions into the nerve fibre cell membrane.

Local anaesthetics may also have similar effects on the membranes of excitable cells such as brain cells and cardiomyocytes, and if excessive amounts of the drug rapidly enter the circulation, signs and symptoms of toxicity in the central nervous system and cardiovascular system will occur.

Pregnant ewes do not show greater sensitivity to ropivacaine compared to non-pregnant ewes. Ropivacaine is well tolerated when administered intravenously in healthy volunteers and clinical experience with this drug suggests a good safety range.

Indirect cardiovascular effects (hypotension, bradycardia) can occur with epidural use of this drug, depending on the degree of parasympathetic blockade.

At high concentrations, the inhibitory effect of bupivacaine on the compound action potentials of class A and C nerve fibres was 16% and 3% stronger than that of ropivacaine hydrochloride, respectively, suggesting that ropivacaine hydrochloride and bupivacaine are similar in their sensory blockade, but ropivacaine hydrochloride is weak in its motor blockade.

At low concentration, ropivacaine hydrochloride mainly blocked sensory nerve fibres, and its blockade of motor nerve fibres was light, i.e., ropivacaine hydrochloride has a high degree of separation of sensory and motor nerve blockade, which has unique advantages for postoperative epidural analgesia.

Characteristic of Bulk Ropivacaine HCL Powder.

Ropivacaine hydrochloride is white or off-white crystal or crystalline powder; odourless. It is soluble in ethanol, soluble in water, almost insoluble in ether.

The chemical structure of Ropivacaine Hydrochloride is similar to that of Mepivacaine and Bupivacaine, so the chemical properties of Ropivacaine Hydrochloride are similar to that of Bupivacaine, the pKa of both of them is similar, and the plasma protein binding rate is 90%.

Ropivacaine hydrochloride is mainly cleared by the liver, and about 50% of it generates PPX, but not cleared by the lungs and heart.

Compared with other amide local anaesthetics, ropivacaine hydrochloride had the shortest T1/2β, the lowest VDSS and the medium CL. After static injection of ropivacaine hydrochloride and bupivacaine, the CL of the former was significantly higher than that of the latter, and the T1/2β was significantly shorter than that of bupivacaine, suggesting that ropivacaine hydrochloride was weaker than bupivacaine in toxicity.